fbpx
Subscribe
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Archive

New study reveals key protein that could help prevent excessive bone loss in osteoporosis

Written by | 4 Jun 2024

Osteoporosis, a condition characterized by porous and fragile bones, poses a significant threat to skeletal health. As the very framework of the human body, bones provide crucial structural… read more.

Researchers identify protein that may help protect against osteoporosis

Written by | 15 Aug 2023

New research published in The FASEB Journal indicates that increasing the expression of a particular gene may help to prevent bone loss associated with postmenopausal osteoporosis. For the study, investigators… read more.

Key protein that drives rheumatoid arthritis damage

Written by | 28 Sep 2022

Scientists have identified a protein known as sulfatase-2 that plays a critical role in the damage caused by rheumatoid arthritis. A chronic disease in which the immune system… read more.

Research strongly suggests COVID-19 virus enters the brain

Written by | 8 Feb 2022

More and more evidence is coming out that people with COVID-19 are suffering from cognitive effects, such as brain fog and fatigue. And researchers are discovering why. The… read more.

Parkinson’s protein blueprint could help fast-track new treatments

Written by | 11 Jan 2022

Researchers have solved a decade-long mystery about a critical protein linked to Parkinson’s disease that could help to fast-track treatments for the incurable disease. The research, published in Nature,… read more.

Suffering from psoriasis? Blame this trio of proteins

Written by | 27 Nov 2021

New study shows there may be a way to help even more psoriasis patients. About 7.5 million Americans suffer from psoriasis, an autoimmune disease that shows up as… read more.

SOPHIA Phase III study of Margenza announces final OS data in HER2-positive breast cancer patients – MacroGenics

Written by | 15 Sep 2021

MacroGenics announced the final overall survival (OS) results of the SOPHIA Phase III study of Margenza (margetuximab-cmkb) in adult patients with metastatic HER2-positive breast cancer. The final OS… read more.

Newsletter Icon

Subscribe for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.

Subscribe

You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.